Letrozole Alone Protocol Versus Using Letrozole and HCG Protocol
Conditions: PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries Interventions: Drug: Letrozole tablets Sponsors: Egymedicalpedia Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials
Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy in Recurrent Epithelial Ovarian Cancer
Conditions: Ovarian Cancer Interventions: Biological: Innocell Autologous Cellular Immunotherapy Sponsors: PhotonPharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials
Diagnosis of Epithelial Ovarian Cancer Using Ovarian Cancer Score (OCS) Test
Conditions: Epithelial Ovarian Cancer; Adnexal Mass Sponsors: Chongqing University Cancer Hospital; Zhejiang Cancer Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; The First Affiliated Hospital of Zhengzhou University; 3D Medicines Corporation Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
Conditions: Recurrent Ovarian Cancer; Folate Receptor-Alpha Positive Interventions: Drug: Mirvetuximab Soravtansine; Drug: Lubricating Eye Drops; Drug: Prednisolone acetate ophthalmic suspension 1% eye drops; Drug: Brimonidine tartrate ophthalmic solution eye drops Sponsors: ImmunoGen, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
OCALA, Fla., April 10, 2024— AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced top-line interim data indicating that combining Ampligen (rintatolimod) with Keytruda (pembrolizumab) in the treatment of recurrent... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 10, 2024 Category: Pharmaceuticals Source Type: clinical trials
Assessment of Endometrial Thickness Among Adolescent and Young Adult Patients on Estrogen Replacement Therapy Using Daily Oral Micronized Progesterone Versus the Etonogestrel Implant.
Conditions: Primary Ovarian Insufficiency; Hypogonadotropic Hypogonadism; Hormone Replacement Therapy Sponsors: University of Colorado, Denver Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Visceral Adiposity Index Differences Between Subtypes of Polycystic Ovary Syndrome
Conditions: Visceral Adiposity Index; Polycystic Ovary Syndrome Sponsors: U şak University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Impact of Different Hemostasis Methods on Ovarian Function and Fertility During Laparoscopic Ovarian Cystectomy of Benign Ovarian Cyst
Conditions: Ovarian Cyst Benign Interventions: Combination Product: the absorbable hemostat and suture; Combination Product: electrocoagulation and suture; Other: suture Sponsors: West China Second University Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
Screening for Ovarian Malignancy
Conditions: Early Detection of Ovarian Cancer Interventions: Diagnostic Test: Assesment of Different NEoplasias in the adenexa model; Diagnostic Test: Risk of malignancy index; Diagnostic Test: Histopathologic examination Sponsors: Ain Shams Maternity Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients With Platinum-Resistant Ovarian Cancer
BASKING RIDGE, N.J.& RAHWAY, N.J., April 3, 2024– Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the first patient has been dosed in... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 3, 2024 Category: Pharmaceuticals Source Type: clinical trials
Radiomics and Machine Learning in the Diagnosis of Ovarian Masses
Conditions: Ovarian Cysts; Ovarian Cancer Interventions: Diagnostic Test: Ultrasound Sponsors: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Conditions: Gynecologic Cancer; Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cavity Cancer Interventions: Drug: FT536; Drug: Fludarabine; Drug: CY Sponsors: Masonic Cancer Center, University of Minnesota Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
Metabolic Differences Between Subtypes of Polycystic Ovary Syndrome
Conditions: Uric Acid Concentration, Serum, Quantitative Trait Locus 7; Polycystic Ovary Syndrome Interventions: Diagnostic Test: Serum uric acid level Sponsors: U şak University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC
Conditions: Epithelial Ovarian Cancer Interventions: Biological: Neoantigen polypeptide vaccine Sponsors: Second Affiliated Hospital of Wenzhou Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
